SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH/MASH serial liver biopsy study

Stephen A. Harrison, Jörn M. Schattenberg, Rebecca Taub, Dominic Labriola, Brandon Hill, Vlad Ratziu